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Abstract: Prostate cancer (PC) displays a strong familial link and genetic factors; genes
regulating inflammation may have a pivotal role in the disease. Epigenetic changes control
chromosomal integrity, gene functions, and, ultimately, carcinogenesis. The most widely studied
epigenetic event in PC is aberrant DNA methylation (hypo- and hypermethylation); besides this,
chromatin remodeling and micro RNA (miRNA) are other studied alterations in PC. These all
lead to genomic instability and inappropriate gene expression. Causative dysfunction of histone
modifying enzymes results in generic and locus-specific changes in chromatin remodeling.
miRNA deregulation also contributes to prostate carcinogenesis, including interference with
androgen-receptor signaling and apoptosis. These epigenetic alterations have the potential to
act as biomarkers for PC for screening and diagnosis as well as prognosis and follow-up. The
variable biological potential for a newly diagnosed PC is one of the biggest challenges. The other
major clinical problem is in the management of castration-resistant PC. Neuroendocrine (NE)
differentiation is one of the putative explanations for the development of castration-resistant
disease. Most advanced and poorly differentiated cancer does not produce prostate-specific
antigen (PSA) in response to disease progression. Circulating and tissue biomarkers like
chromogranin A (CgA) thus become important tools. There is the potential to use various genetic
and epigenetic alterations and NE differentiation as therapeutic targets in the management of
PC. However, we are still some distance from developing clinically effective tools. Valuable
insights into the nature of NE differentiation in PC have been gained in the last decades, but
additional understanding of its pathogenetic mechanisms is needed. This will help in devising
novel therapeutic strategies to develop targeted therapies. CgA has the potential to become an
important marker of advanced castration-resistant PC in cases where prostate-specific antigen
can no longer be relied upon. Aberrant androgen-receptor signaling at various levels provides
evidence of the importance of this pathway for the development of castration-resistant PC. Many
epigenetic influences – in particular, the role of changing miRNA expression – provide valuable
insights. Currently, massive sequencing efforts are underway to define important somatic genetic
alterations (amplifications, deletions, point mutations, translocations) in PC, and these alterations
hold great promise as prognostic markers and for predicting response to therapy.
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It is estimated that there are nearly 2.8 million men living with a history of prostate
cancer (PC) in the USA, and that an additional 241,740 cases will be diagnosed in
2012.1 The median age at diagnosis is 67 years.2 PC affects elderly men and incidence
increases with age. The percentage probability of developing PC increases with age:
it is 0.01% for those under 40 years of age, 2.63% for those aged between 40 and
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59 years, 6.84% for those between 60 and 69, and 12.54%
for those aged over 70 years. During 2006–2008, there was a
lifetime risk of 16.48% in the USA.3 Similarly, in Europe, PC
is the most common solid neoplasm and the most common
form of cancer in men (202,100 incident cases, 18.1% of all
incident cases in 2004).4 One of the remarkable features of
PC is wide variation in incidence across ethnic groups. As an
example, there is a high prevalence among African-American
(137 cases/100,000 population) compared with the Asian
population (,10 cases/100,000 population).5
The mechanisms involved in the development of PC are
still to be determined; however, it is evident that both genetic
and epigenetic changes contribute to its development and
progression. “Epigenetic” refers to alterations of the DNA
or associated proteins, without disturbing the DNA sequence
and carrying of information regarding gene expression
during cell division.6 Altered epigenetic gene regulation
is involved in the genesis and progression of PC. Aberrant
epigenetic events include DNA hypo- and hypermethylation,
chromatin remodeling, altered histone modifications, and
changes in micro RNA (miRNA) expression. All these events
have been detected in a range of genes associated with PC
and produce heritable changes in gene expression without
altering the DNA coding sequence. The list of aberrantly
epigenetically regulated genes continues to grow; only a few
genes have, so far, produced promising results as potential
tumor biomarkers for early diagnosis and risk stratification.
Epigenetic alterations have the potential to become valuable
tools for the management of PC. This is due to reversibility
of epigenetic aberrations with modulators that demethylate
DNA and inhibit histone deacetylases, leading to reactivation
of silenced genes. Pharmacologic compounds that reverse
their nature can target these alterations.
In this brief review, effort is made to review the current
evidence to improve understanding of the various genetic
and epigenetic influences, in particular NE differentiation,
in the causation and progress of PC.

to stimulate the survival, growth, motility, and metastatic
potential of prostatic carcinoma cells. NE-differentiated PC
either involves focal NE cells in the milieu of adenocarcinoma
or tumors composed exclusively of NE cells (the rare and
aggressive small cell carcinoma and carcinoid/carcinoid-like
tumor). There is lack of consensus as to the independent
prognostic value of focal NE differentiation in PC; however,
a significant body of current evidence suggests that it has an
influence on prognosis related to hormone-resistant tumors.
There are reports as to its role in the conversion to a hormoneresistant phenotype.
The various transcription factors responsible in the
development of NE characteristics through prostatic
adenocarcinoma cells include signal transducer and activator
of transcription 3, cAMP response element-binding protein,
early growth response protein 1, c-Fos, and nuclear factor
kappa B.7 The different molecular markers of NE cells
include chromogranin A (CgA), neuron-specific enolase,
B-cell lymphoma 2, and the androgen receptor.8 The NE
cells secrete a myriad of neuropeptides, which trigger growth
and survival responses in androgen-independent PC cells.
These neuropeptides are bombesin, neurotensin, parathyroid
hormone-related protein, serotonin, and calcitonin.6 PC cell
receptors that play a role in these processes include the
gastrin-releasing peptide receptor, neurotensin receptors, and
the epidermal growth-factor receptor. Signal-transduction
molecules activated by these neuropeptides include Src,
focal adhesion kinase, extracellular signal-regulated kinases,
and phosphatidylinositol 3-kinases/Akt, with subsequent
activation of E twenty-six-like transcription factor 1, nuclear
factor kappa B, and c-Myc transcription factors. A multitude
of genes are then expressed by PC cells, which are involved
in proliferation, anti-apoptosis, migration, metastasis, and
angiogenesis. Targeting of these pathways at multiple
levels can be exploited to inhibit the process by which NE
cells contribute to the progression of androgen-independent
treatment-refractory PC.

Neuroendocrine differentiation
in PC

Genetic factors in the etiology
of PC

Neuroendocrine (NE) differentiation in PC represents
a heterogeneous group of entities. NE in differentiation
has received increasing attention in recent years due to
prognostic and therapeutic implications. The NE pattern in
castration-resistant prostate cancer (CRPC) may prove useful
in selecting potential responders to target therapies such as
somatostatin analogues. NE cells are derived from non-NE
PC cells and secrete factors that can act in a paracrine manner

In view of the strong ethnic predisposition, strong family
association, and familial clustering, there is a strong
likelihood that genetic factors play an important role in the
development of PC. In the last several years, genome-wide
association studies (GWASs) have identified over 36 germ
line variants of genes that have shown significant association
with PC susceptibility. The wide variation in the incidence
of PC in different ethnic groups supports the genetic etiology
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of PC.5 Aside from age and ethnicity, a positive family history
is also a significant risk factor.9
Over 40 PC susceptibility loci explaining approximately
25% of the familial risk have been identified. The majority of
GWASs reported to date have been conducted in populations
of European, African-American,10 and Japanese ancestrys.11
An up-to-date catalog of published GWASs is available
at the US National Institutes of Health National Human
Genome Research Institute website (http://www.genome.
gov/gwastudies/).
The genetic factors have been used to assess risk of PC
development, risk of advanced disease, and duration of
response to hormonal therapies. In diagnosis and screening,
there is significant potential for the use of urine measurements
of prostate cancer antigen 3 RNA and the transmembrane
protease like serine 2 v-ets erythroblastosis viruses and E26
oncogene homolog (avian) (TMPRSS2-ERG) gene fusion.
Multiple groups12,13 have developed gene-expression signatures from primary prostate tumors correlating with poor
prognosis, and attempts to improve and standardize these
signatures as diagnostic tests have been presented. Massive
sequencing efforts are underway to define important somatic
genetic alterations (amplifications, deletions, point mutations, translocations) in PC, and these alterations hold great
promise as prognostic markers and for predicting response
to therapy.12

Epigenetic factors influencing
carcinogenesis
“Epigenetic alterations” are heritable changes in gene
expression that occur without changes in DNA sequence.14
Epigenetic changes control chromosomal integrity,
gene functions, and, ultimately, carcinogenesis. The
aberrant epigenetic events in PC include DNA hypo- and
hypermethylation, chromatin remodeling, altered histone
modifications, and changes in miRNA expression. The
most studied of these is DNA methylation. However, it is
not completely understood what induces these epigenetic
alterations in cancer; in addition, their role in prostate
tumorigenesis is being evaluated. Identification of the
epigenetic modifications involved in the development and
progression of PC will aid in identifying novel therapeutic
targets and indicators of biological and diagnostic markers.

DNA hypo- and hypermethylation
DNA methylation plays an important role in regulating gene
activity, the DNA repair process, and recombination and replication. DNA methylation involves the addition of a methyl group
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to the 5′-carbon of cytosine in the phosphodiesterase bond
between cytosine and guanine (CpG) dinucleotide sequences;
a family of DNA methyltransferases catalyzes this step.
DNA methylation can regulate gene activity via two
mechanisms. First, methylation of CpG dinucleotides within
transcription-factor binding sites can inhibit transcriptionfactor binding and, therefore, directly influence gene
activity.15 Secondly, methylated CpG dinucleotides act as
binding sites for methyl CpG binding proteins, which are
associated with other factors such as histone deacetylases,
involved in establishing repressive chromatin structures.16
These methylation changes have been implicated in the
tumorigenesis of PC; however, these changes are complex.
They involve both hypo- and hypermethylation. Aberrant
DNA hypermethylation occurs when there is an increase in
DNA methylation at unmethylated regions. Hypermethylation
at gene promoters can lead to its inactivation. In contrast,
“DNA hypomethylation” is the demethylation of normally
methylated DNA and can lead to chromosomal instability
and activation of proto-oncogenes.

Chromatin remodeling and histone
modifications
Chromatin is composed of a protein core, which is made
up of eight histones, around which 147 bp of DNA is
wrapped.17 Histones not only provide physical support to
DNA but also are involved in regulating its transcription,
repair, and replication. 15,16,18 Various posttranslational
biochemical modifications such as acetylation, methylation,
and phosphorylation can potentially affect the histone tail.15,19
This results in the histone code, which involves structural and
translational changes. These alterations decrease the affinity
of histones for DNA. Consequently, an “open” chromatin
conformation results and allows the gene transcription to
take place. Contrarily, histone deacetylation is associated
with closed, or repressive, chromatin. Two enzymes involved
in creating an equilibrium state between acetylation and
deacetylation are histone acetyltransferases and histone
deacetylases. Similarly, histone methylation may be associated
with either transcriptional promotion or repression. The
histone methylation is modified by two enzymes – histone
methyltransferases and histone demethylases.15,16,18 In malignant
cells, genome-wide histone modification is also altered in
concert with changes in DNA methylation.20 Interestingly, the
same repressive histone marks were identified in certain genes
with tumor-suppressor behavior that are not silenced by DNA
methylation.21 Accordingly, alterations in the expression of key
histone-modulating enzymes (histone deacetylases, histone
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acetyltransferases, histone methyltransferases, and histone
demethylases) have been associated with cancer development
and progression.13,22,23

miRNA
“Micro RNAs” are endogenous non-coding RNAs that
can interfere with protein expression either by inducing
the cleavage of specific target messenger RNAs or, in
most cases, by inhibiting their translation.24 Review of the
contemporary literature reveals that though over 48 miRNAs
have been implicated in PC, only a few have been shown
to be of clinical significance. The most significant clinical
impact of miRNA is to provide an alternative mechanism
sustaining androgen-independent growth.25 It has been
shown that miRs-221, -222, -23b, -27b, -15a, -16-1, and
-203 are differentially expressed in the hormone-sensitive
LNCaP cell line and the hormone-resistant LNCaP-abl cell
line.26 This suggests that these miRNAs may characterize
certain subtypes of human CRPC. In a recent work, Sun
and colleagues suggested that altered miR-221/-222 and
miR-23b/-27b expression may be associated with the
CRPC process.27 However, it has also been suggested that
androgens may play a role in downregulation of miR221/-222.23 Other miRNAs are also potential modulators
of androgen receptor-mediated signaling. Besides altering
androgen-receptor signaling, miRNAs are also implicated in
attributing immortality to PC cells through the avoidance of
apoptosis. This is achieved by overexpression of miR-2128
and downregulation miR-34a29 and miR-34c.30

Current markers
The biological potential of PC is highly variable. The majority
of PCs is indolent and is diagnosed in the sixth to eighth
decades of life. The majority of elderly males is likely to die
of other causes and not from cancer. Therefore, it is often
unnecessary to subject them to invasive and potentially
morbid treatment options. Currently, PSA is the only
surrogate marker for diagnosis, prognosis, and follow-up of
patients with PC. It is an excellent marker in the follow-up of
PC patients managed medically or surgically. However, there
are significant issues with PSA’s diagnostic, screening,31 and
predictive/prognostic value.32

Potential new markers
There is an urgent clinical need for the identification of
novel biomarkers in PC. Current development in the field
of proteomic techniques holds the promise of providing
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new tools with which to find novel PC biomarkers for early
diagnosis and prognosis.
CgA is an acidic glycoprotein that is commonly
expressed by NE cells and constitutes one of the most
profuse components of secretory granules. Its concentration
is thought to be elevated in relation to NE differentiation of
PC. Most advanced PC becomes anaplastic and does not
express PSA in tissue or produce PSA in congruence with
the increasing bulk of the cancer. In such a situation, PSA
becomes an unreliable marker of disease progression. Thus,
CgA is a useful predictive marker in patients with prostatic
cancer who have a lower PSA level.
CgA and PSA are complementary tumor markers
in CRPC.33 CgA may help in predicting the response to
docetaxel therapy. Rising CgA levels during therapy may
be associated with poor prognosis whereas CgA response is
likely to be associated with clinical response.
It is known that NE cells in the prostate do not contain
androgen receptors and are not regulated by androgens.
PSA expression can be stimulated by androgen through
androgen receptors, so it is suggested that cases of PC
associated with low serum PSA and high serum CgA,
which would have more NE cells with less androgen
receptors, may show resistance to endocrine therapy and a
poor prognosis. Therefore, serum CgA tends to be elevated
in high-grade PC cases. Hence, it can be used to fill any
gap left by PSA and, when combined with serum PSA,
the serum marker may effectively predict prognosis after
endocrine therapy. CgA expression in PC biopsies is an
independent extrapolative factor of hormone-refractory
disease in patients with newly diagnosed PC on early
androgen-deprivation therapy.

Genetic markers
The use of genetic markers has the potential to aid disease
screening and to improve prognostic discrimination and
prediction of response to treatment. However, most markers
have not been prospectively validated for providing useful
prognostic or predictive information or improvement upon
clinicopathologic parameters already in use. Significant
efforts are underway to develop these research findings into
clinically useful diagnostic tests in order to improve clinical
decision-making.

Epigenetic biomarkers
Among the promising serum epigenetic markers in PC
for cancer detection due to DNA methylation are GSTP1,
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PTGS2, RPRM, TIG1, and one related to miRNA – miR-141.
The tissue markers related to DNA methylation include
GSTP1, APC, PTGS2, and MDR1. Among the various
tissue markers used in the prognosis and prediction of the
biological potential of the tumor are APC, CD44, PITX2, and
PTGS2; H3K4me, H3K4me2, H3K18Ac, EZH2, and LSD1
(DNA methylation); and miRs-34c, -96, -135b, and -194
(miRNA).34

Conclusion
In the last few decades, valuable insights have been gained
regarding the nature of NE differentiation in PC in the
last decades; further understanding of its pathogenetic
mechanisms is still required. Understanding of the
development and progression of PC, and the factors that
drive the development of androgen independence, are better
understood in light of NE differentiation. The fact that most
cancers eventually produce androgen-independent clones
highlights the variety of genetic changes in the primary
tumor that result in phenotypically distinct cells with different
cellular capabilities, and their own characteristic response to
the dynamic microenvironment. This will help in devising
novel therapeutic strategies to develop targeted therapies.
CgA has the potential to become an important marker of
advanced CRPC when PSA can no longer be relied upon.
Aberrant androgen-receptor signaling at various levels
provides evidence of the importance of this pathway for
the development of CRPC. Many epigenetic influences – in
particular, the role of changing miRNA expression – provide
valuable insights. Massive sequencing efforts are underway to
define important somatic genetic alterations (amplifications,
deletions, point mutations, translocations) in PC, and these
alterations hold great promise as prognostic markers and for
predicting response to therapy.
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